Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge

BACKGROUND: As the number of indicated malignancies for which immune checkpoint inhibitor therapy such as pembrolizumab grows the descriptions of associated immune-related adverse events (irAEs) increases as well. On rare occasions immunotherapy can lead to development of Hemophagocytic Lymphohistio...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalmuk, James, Puchalla, Jon, Feng, Gong, Giri, Anshu, Kaczmar, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996173/
https://www.ncbi.nlm.nih.gov/pubmed/32025343
http://dx.doi.org/10.1186/s41199-020-0050-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996173/
https://www.ncbi.nlm.nih.gov/pubmed/32025343
http://dx.doi.org/10.1186/s41199-020-0050-3

Ejemplares similares